Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depression

Alan P. Kozikowski, J. Brek Eaton, Krishna Mohan Bajjuri, Sheela K. Chellappan, Yihua Chen, Sudhakar Karadi, Rong He, Barbara Caldarone, Michael Manzano, Po Wai Yuen, Ronald J. Lukas

Research output: Contribution to journalArticle

Abstract

AMOP-H-OH (sazetidine-A; 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn- 1-ol) and some sulfur-bearing analogues were tested for their activities in vitro against human α4β2-, α4β4-, α3β4*- and α1*-nicotinic acetylcholine receptors (nAChRs). AMOP-H-OH was also assessed in an antidepressant efficacy model. AMOP-H-OH and some of its analogues have high potency and selectivity for α4β2-nAChRs over other nAChR subtypes. Effects are manifested as partial agonism, perhaps reflecting selectivity for high sensitivity (α4)3(β2) 2-nAChRs. More prolonged exposure to AMOP-H-OH and its analogues produces inhibition of subsequent responses to acute challenges with full nicotinic agonists, again selectively for α4β2-nAChRs over other nAChR subtypes. The inhibition is mediated either via antagonism or desensitization of nAChR function, but the degree of inhibition of α4β2-nAChRs is limited by the partial agonist activity of the drugs. Certain aspects of the in vitro pharmacology suggest that AMOP-H-OH and some of its analogues have a set of binding sites on α4β2-nAChRs that are distinct from those for full agonists. The in vitro pharmacological profile suggests that peripheral side effects of AMOP-H-OH or its analogues would be minimal and that their behavioral effects would be dominated by central nAChR actions. AMOP-H-OH also has profound and high potency antidepressant-like effects in the forced swim test. The net action of prolonged exposure to AMOP-H-OH or its analogues, as for nicotine, seems to be a selective decrease in α4β2-nAChR function. Inactivation of nAChRs may be a common neurochemical endpoint for nicotine dependence, its treatment, and some of its manifestations, including relief from depression.

Original languageEnglish (US)
Pages (from-to)1279-1291
Number of pages13
JournalChemMedChem
Volume4
Issue number8
DOIs
StatePublished - Aug 3 2009
Externally publishedYes

Fingerprint

Nicotinic Receptors
Pharmacology
Depression
Ligands
Nicotine
Antidepressive Agents
Bearings (structural)
Nicotinic Agonists
Tobacco Use Disorder
Sulfur
Binding Sites
Pharmaceutical Preparations
Inhibition (Psychology)
In Vitro Techniques

Keywords

  • AMOP-H-OH
  • Depression
  • nAChRs
  • Neurological agents
  • Nicotine
  • Receptors
  • Sazetidine-A

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry
  • Molecular Medicine

Cite this

Kozikowski, A. P., Brek Eaton, J., Bajjuri, K. M., Chellappan, S. K., Chen, Y., Karadi, S., ... Lukas, R. J. (2009). Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depression. ChemMedChem, 4(8), 1279-1291. https://doi.org/10.1002/cmdc.200900079

Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depression. / Kozikowski, Alan P.; Brek Eaton, J.; Bajjuri, Krishna Mohan; Chellappan, Sheela K.; Chen, Yihua; Karadi, Sudhakar; He, Rong; Caldarone, Barbara; Manzano, Michael; Yuen, Po Wai; Lukas, Ronald J.

In: ChemMedChem, Vol. 4, No. 8, 03.08.2009, p. 1279-1291.

Research output: Contribution to journalArticle

Kozikowski, AP, Brek Eaton, J, Bajjuri, KM, Chellappan, SK, Chen, Y, Karadi, S, He, R, Caldarone, B, Manzano, M, Yuen, PW & Lukas, RJ 2009, 'Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depression', ChemMedChem, vol. 4, no. 8, pp. 1279-1291. https://doi.org/10.1002/cmdc.200900079
Kozikowski, Alan P. ; Brek Eaton, J. ; Bajjuri, Krishna Mohan ; Chellappan, Sheela K. ; Chen, Yihua ; Karadi, Sudhakar ; He, Rong ; Caldarone, Barbara ; Manzano, Michael ; Yuen, Po Wai ; Lukas, Ronald J. / Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depression. In: ChemMedChem. 2009 ; Vol. 4, No. 8. pp. 1279-1291.
@article{7ffc6c2a51a04f528c6379010d7d30fa,
title = "Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depression",
abstract = "AMOP-H-OH (sazetidine-A; 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn- 1-ol) and some sulfur-bearing analogues were tested for their activities in vitro against human α4β2-, α4β4-, α3β4*- and α1*-nicotinic acetylcholine receptors (nAChRs). AMOP-H-OH was also assessed in an antidepressant efficacy model. AMOP-H-OH and some of its analogues have high potency and selectivity for α4β2-nAChRs over other nAChR subtypes. Effects are manifested as partial agonism, perhaps reflecting selectivity for high sensitivity (α4)3(β2) 2-nAChRs. More prolonged exposure to AMOP-H-OH and its analogues produces inhibition of subsequent responses to acute challenges with full nicotinic agonists, again selectively for α4β2-nAChRs over other nAChR subtypes. The inhibition is mediated either via antagonism or desensitization of nAChR function, but the degree of inhibition of α4β2-nAChRs is limited by the partial agonist activity of the drugs. Certain aspects of the in vitro pharmacology suggest that AMOP-H-OH and some of its analogues have a set of binding sites on α4β2-nAChRs that are distinct from those for full agonists. The in vitro pharmacological profile suggests that peripheral side effects of AMOP-H-OH or its analogues would be minimal and that their behavioral effects would be dominated by central nAChR actions. AMOP-H-OH also has profound and high potency antidepressant-like effects in the forced swim test. The net action of prolonged exposure to AMOP-H-OH or its analogues, as for nicotine, seems to be a selective decrease in α4β2-nAChR function. Inactivation of nAChRs may be a common neurochemical endpoint for nicotine dependence, its treatment, and some of its manifestations, including relief from depression.",
keywords = "AMOP-H-OH, Depression, nAChRs, Neurological agents, Nicotine, Receptors, Sazetidine-A",
author = "Kozikowski, {Alan P.} and {Brek Eaton}, J. and Bajjuri, {Krishna Mohan} and Chellappan, {Sheela K.} and Yihua Chen and Sudhakar Karadi and Rong He and Barbara Caldarone and Michael Manzano and Yuen, {Po Wai} and Lukas, {Ronald J.}",
year = "2009",
month = "8",
day = "3",
doi = "10.1002/cmdc.200900079",
language = "English (US)",
volume = "4",
pages = "1279--1291",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depression

AU - Kozikowski, Alan P.

AU - Brek Eaton, J.

AU - Bajjuri, Krishna Mohan

AU - Chellappan, Sheela K.

AU - Chen, Yihua

AU - Karadi, Sudhakar

AU - He, Rong

AU - Caldarone, Barbara

AU - Manzano, Michael

AU - Yuen, Po Wai

AU - Lukas, Ronald J.

PY - 2009/8/3

Y1 - 2009/8/3

N2 - AMOP-H-OH (sazetidine-A; 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn- 1-ol) and some sulfur-bearing analogues were tested for their activities in vitro against human α4β2-, α4β4-, α3β4*- and α1*-nicotinic acetylcholine receptors (nAChRs). AMOP-H-OH was also assessed in an antidepressant efficacy model. AMOP-H-OH and some of its analogues have high potency and selectivity for α4β2-nAChRs over other nAChR subtypes. Effects are manifested as partial agonism, perhaps reflecting selectivity for high sensitivity (α4)3(β2) 2-nAChRs. More prolonged exposure to AMOP-H-OH and its analogues produces inhibition of subsequent responses to acute challenges with full nicotinic agonists, again selectively for α4β2-nAChRs over other nAChR subtypes. The inhibition is mediated either via antagonism or desensitization of nAChR function, but the degree of inhibition of α4β2-nAChRs is limited by the partial agonist activity of the drugs. Certain aspects of the in vitro pharmacology suggest that AMOP-H-OH and some of its analogues have a set of binding sites on α4β2-nAChRs that are distinct from those for full agonists. The in vitro pharmacological profile suggests that peripheral side effects of AMOP-H-OH or its analogues would be minimal and that their behavioral effects would be dominated by central nAChR actions. AMOP-H-OH also has profound and high potency antidepressant-like effects in the forced swim test. The net action of prolonged exposure to AMOP-H-OH or its analogues, as for nicotine, seems to be a selective decrease in α4β2-nAChR function. Inactivation of nAChRs may be a common neurochemical endpoint for nicotine dependence, its treatment, and some of its manifestations, including relief from depression.

AB - AMOP-H-OH (sazetidine-A; 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn- 1-ol) and some sulfur-bearing analogues were tested for their activities in vitro against human α4β2-, α4β4-, α3β4*- and α1*-nicotinic acetylcholine receptors (nAChRs). AMOP-H-OH was also assessed in an antidepressant efficacy model. AMOP-H-OH and some of its analogues have high potency and selectivity for α4β2-nAChRs over other nAChR subtypes. Effects are manifested as partial agonism, perhaps reflecting selectivity for high sensitivity (α4)3(β2) 2-nAChRs. More prolonged exposure to AMOP-H-OH and its analogues produces inhibition of subsequent responses to acute challenges with full nicotinic agonists, again selectively for α4β2-nAChRs over other nAChR subtypes. The inhibition is mediated either via antagonism or desensitization of nAChR function, but the degree of inhibition of α4β2-nAChRs is limited by the partial agonist activity of the drugs. Certain aspects of the in vitro pharmacology suggest that AMOP-H-OH and some of its analogues have a set of binding sites on α4β2-nAChRs that are distinct from those for full agonists. The in vitro pharmacological profile suggests that peripheral side effects of AMOP-H-OH or its analogues would be minimal and that their behavioral effects would be dominated by central nAChR actions. AMOP-H-OH also has profound and high potency antidepressant-like effects in the forced swim test. The net action of prolonged exposure to AMOP-H-OH or its analogues, as for nicotine, seems to be a selective decrease in α4β2-nAChR function. Inactivation of nAChRs may be a common neurochemical endpoint for nicotine dependence, its treatment, and some of its manifestations, including relief from depression.

KW - AMOP-H-OH

KW - Depression

KW - nAChRs

KW - Neurological agents

KW - Nicotine

KW - Receptors

KW - Sazetidine-A

UR - http://www.scopus.com/inward/record.url?scp=68149157424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68149157424&partnerID=8YFLogxK

U2 - 10.1002/cmdc.200900079

DO - 10.1002/cmdc.200900079

M3 - Article

C2 - 19569163

AN - SCOPUS:68149157424

VL - 4

SP - 1279

EP - 1291

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 8

ER -